NCT01221376
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) treatment 2 unknown_status NCT01374139
Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects treatment 1 completed NCT01159028
Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS treatment 1 completed NCT05456191
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) treatment 3 active_not_recruiting NCT01819389
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance treatment 3 completed NCT05007873
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase treatment 2 recruiting NCT04971226
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP treatment 3 active_not_recruiting NCT01844765
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. treatment 2 completed NCT02115386
Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib treatment 3 terminated NCT04877522
Asciminib Roll-over Study treatment 4 recruiting NCT01437202
Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia No drug interventions Not Available Not Available completed NCT02903277
National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent No drug interventions Not Available Not Available unknown_status NCT01464411
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan No drug interventions Not Available Not Available unknown_status NCT02896842
A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML No drug interventions treatment 2 completed NCT01774630
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) treatment 2 completed NCT02885766
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene treatment 1 / 2 unknown_status NCT01768689
Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia No drug interventions treatment Not Available completed NCT02389972
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study Not Available Not Available completed NCT00171223
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha treatment 2 completed NCT03090477
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients No drug interventions health_services_research Not Available completed NCT01602952
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI treatment 1 / 2 completed NCT02687425
Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia treatment 2 unknown_status NCT02421926
Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) Not Available Not Available withdrawn NCT01511289
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients treatment 3 completed NCT02480608
Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) treatment 1 / 2 completed NCT04258943
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT04070443
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase treatment 2 active_not_recruiting NCT03241199
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia treatment 2 unknown_status NCT00171158
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis treatment 2 completed NCT03459534
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs treatment 3 recruiting NCT03885830
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients Not Available Not Available completed NCT04578847
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) treatment 2 active_not_recruiting NCT01456676
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy treatment 1 completed NCT01916785
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy) treatment 2 completed NCT04883125
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment treatment 2 completed NCT00316953
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate treatment 1 completed NCT00003145
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia treatment 2 completed NCT00096161
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant treatment 2 completed NCT00101088
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia treatment 1 terminated NCT03622788
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant treatment 1 / 2 recruiting NCT00719888
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease treatment 2 active_not_recruiting NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction treatment 1 completed NCT00351975
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases treatment 1 completed NCT01426334
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate treatment 1 terminated NCT02210858
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders treatment 1 / 2 completed NCT03267186
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant treatment 2 completed NCT03333486
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer treatment 2 active_not_recruiting NCT01751425
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors treatment 1 terminated NCT00023920
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia treatment 2 terminated NCT03399773
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes treatment 2 recruiting NCT00003694
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase treatment 2 completed NCT00030394
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia treatment 2 completed NCT01445080
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia treatment 1 / 2 completed NCT00049192
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia treatment 2 completed NCT01858740
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children treatment 2 completed NCT00060372
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer treatment 1 completed NCT00796068
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant treatment 2 completed NCT02730195
Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia treatment 2 terminated NCT00036738
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib treatment 2 completed NCT04282343
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer No drug interventions health_services_research Not Available completed NCT00702403
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML treatment 1 / 2 completed NCT00006364
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia treatment 2 completed NCT01670084
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia treatment 2 withdrawn NCT05972577
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study No drug interventions supportive_care Not Available active_not_recruiting NCT03128359
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant supportive_care 2 completed NCT04083170
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers treatment 2 terminated NCT03739606
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer treatment 2 withdrawn NCT00015834
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia treatment 1 / 2 completed NCT04694820
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia No drug interventions supportive_care Not Available completed NCT03096782
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma treatment 2 completed NCT02877082
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients prevention 2 terminated NCT00054431
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia treatment 2 completed NCT03630991
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy treatment 1 recruiting NCT03941769
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II supportive_care 1 / 2 completed NCT03195010
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia No drug interventions supportive_care 2 terminated NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies supportive_care 2 completed NCT01760655
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies treatment 2 completed NCT02734823
Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor No drug interventions Not Available Not Available withdrawn NCT06409936
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML treatment 2 not_yet_recruiting NCT05439889
Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission No drug interventions Not Available Not Available recruiting NCT05413915
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML treatment 3 recruiting NCT00171249
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia treatment 2 completed NCT00027144
Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase No drug interventions treatment 1 completed NCT00037882
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron treatment 2 terminated NCT00297570
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy treatment 3 unknown_status NCT04925479
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia treatment 1 / 2 recruiting NCT00101660
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib treatment 2 completed NCT00103844
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia treatment 2 completed